Breast Cancer accounted for a 12.2% share of the global clinical trials within the Oncology therapy area in 2020, registering a decrease of 0.7% when compared with the last ten-year average of 12.9% share, according to GlobalData.
Go deeper with GlobalData
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
Non-industry sponsored trials outnumber industry sponsored trials for Breast Cancer
Industry sponsored trials held a 45.6% share of all the clinical trials for Breast Cancer indication in 2020, registering an increase of 9.0% when compared with the ten-year average of 36.6%. Non-industry sponsored trials accounted for a 54.4% share in 2020, marking a decrease of 9.0% over the ten-year average of 63.4%.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
Top regions of industry sponsored Breast Cancer trials
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataAsia-Pacific was the top region for industry sponsored Breast Cancer trials, accounting for a 63.1% share in 2020, when compared with the five-year average of 51.2% and ten-year average of 43.6%.
North America was at the second position with a 47.6% share in 2020, over the five-year average of 54.8% and ten-year average of 54.6%, followed by Europe with a 29.5% share in 2020, as against five-year and ten-year averages of 39.6% and 45.8% respectively.
South and Central America stood fourth with a 7.4% share in 2020, compared with the five-year average of 6.4% and ten-year average of 8.0%, followed by Middle East and Africa with a 6.3% share in 2020, over five-year and ten-year averages of 7.8% and 9.0% respectively.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
The US was the top country for industry sponsored Breast Cancer trials, accounting for a 46.1% share in 2020, as against the five-year average of 53.3% and ten-year average of 52.6%.
China held a 37.6% share in 2020, over the five-year average of 19.8% and ten-year average of 13.6%, followed by Spain with a 16.6% share in 2020, compared with the five-year and ten-year averages of 23.0% and 23.8% respectively.
The UK held a 14.8% share in 2020, as against the five-year average of 16.6% and ten-year average of 17.7%.
South Korea held a 14.0% share in 2020, over the five-year and ten-year averages of 13.3% and 13.0% respectively.
Top regions of non-industry sponsored Breast Cancer trials
Asia-Pacific was the top region for non-industry sponsored Breast Cancer trials, accounting for a 46.2% share in 2020 when compared with the five-year average of 40.5% and ten-year average of 39.3%.
North America was at the second position with a 27.9% share in 2020, over the five-year and ten-year averages of 32.7% and 34.2% respectively, followed by Europe with an 18.2% share in 2020, as against the five-year average of 20.5% and ten-year average of 22.3%.
Middle East and Africa stood at the fourth position with a 6.8% share in 2020, compared with the five-year average of 6.6% and ten-year average of 4.7%, followed by South and Central America with a 1.2% share in 2020, over the five-year and ten-year averages of 1.6% and 1.6% respectively.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
China was the top country for non-industry sponsored Breast Cancer trials, accounting for a 32.4% share in 2020, as against the five-year average of 21.7% and ten-year average of 16.0%.
The US held a 25.6% share in 2020, over the five-year average of 29.6% and ten-year average of 31.4%, followed by India with a 5.0% share, compared with the five-year and ten-year averages of 5.1% and 3.1% respectively.
Spain held a 3.8% share in 2020, as against the five-year average of 2.3% and ten-year average of 2.4%.
Iran held a 3.2% share in 2020, over the five-year average of 3.7% and ten-year average of 2.4%.
Phase I trials lead industry sponsored clinical trials for Breast Cancer in 2020
Phase I trials held a 48.5% share of industry sponsored clinical trials for Breast Cancer in 2020, over the five-year average of 47.4% and ten-year average of 44.3%.
Phase II trials held a 33.7% share in 2020, as against the five-year average of 33.1% and ten-year average of 32.8%. Phase III trials held a 13.5% share in 2020, compared with the five-year and ten-year averages of 13.7% and 14.1% respectively.
Phase IV trials held a 4.4% share in 2020, over the five-year average of 5.8% and ten-year average of 8.8%.
Phase II trials lead non-industry sponsored clinical trials for Breast Cancer in 2020
Phase II trials held a 53.8% share of non-industry sponsored clinical trials for Breast Cancer in 2020, over the five-year average of 61.2% and ten-year average of 61.7%.
Phase I trials held a 21.4% share in 2020, as against the five-year average of 14.0% and ten-year average of 14.7%. Phase IV trials held a 13.2% share, compared with the five-year and ten-year averages of 13.3% and 12.3% respectively.
Phase III trials held a 11.5% share in 2020, over the five-year average of 11.5% and ten-year average of 11.3%.
Methodology:
The clinical trials data used for the analyses were extracted from the Clinical Trials Database of GlobalData’s Pharma Intelligence Center. Clinical Trials are sourced from numerous government, non-government and company clinical trial registries worldwide alongside clinical research publications, scientific conferences, company websites, SEC filings and more. The information is gathered by a combination of automation and secondary research to ensure accuracy and validity. A small number of Phase 0, Phase I/II, Phase II/III, and Phase III/IV trials were combined with Phase I, Phase II, Phase III, and Phase IV trials, respectively.
